Budget impact analysis of antiplatelet therapy with ticagrelor and clopidogrel in patients with acute coronary syndrome after coronary artery bypass surgery

Abstract

Aim. Clinical and economic examinations were made to study whether it is appropriate to use antiplatelet therapy (APT) with ticagrelor in combination with acetylsalicylic acid (ASA) versus a combination of clopidogrel and ASA in patients with acute coronary syndrome (ACS) following coronary artery bypass surgery (CABS). Materials and methods. A budget impact analysis was used. Data on the efficiency and safety of APT were taken from a relevant analysis in the subgroups of the randomized controlled trial PLATO. Direct medical cost due to APT and expenses on therapy for acute myocardial infarction, stroke, and massive bleeding, and those on medical care for patients dying from cardiovascular events and other causes, as well as indirect cost - gross domestic product (GDP) losses due to untimely death, were taken into account. The findings were assessed from the perspectives of society. Results. The analysis indicated that direct medical costs per patient following CABS, both in case of calculation based on the recorded price for ticagrelor and on the median registered prices for clopidogrel generics, and based on the auction prices for comparison agents proved to be lower when clopidogrel was administered because of the higher cost of ticagrelor-based APT. At the same time GDP losses due to untimely death, as calculated per patient with ACS during post-CABS therapy with clopidogrel + ASA, were more than twice above average losses per patient taking ticagrelor in combination with ACA (107,122 and 221,645 rubles, respectively). From the registered price for ticagrelor and the median registered prices for clopidogrel generics, the total costs per patient with ACS following CABS were lower if Brilinta was used in combination with ASA versus therapy with clopidogrel in combination with ASA (210,092 and 273,257 rubles per year, respectively; the cost savings were 63,165 rubles per patient per year when ticagrelor was administered). On the basis of the auction prices for comparison drugs, the total costs per patient with ACS after CABS proved to be lower if Brilinta was used in combination with ASA versus therapy with brand name clopidogrel in combination with ASA (201,018 and 293,982 rubles per patients year, respectively; the cost savings were 92,963 rubles per patient per year when ticagrelor was used). Conclusion. The use of ticagrelor in combination with ASA ensures resource savings to treat ACS patients undergoing CABS as compared with a regiment including a combination of clopidogrel and ASA.

References

  1. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2015;37(3):267-315. doi: 10.1093/eurheartj/ehv320
  2. Kei AA, Florentin M et al. Antiplatelet Drugs: What comes next? Clinical and Applied Thrombosis. Hemostasis. 2011;7(1):9-26. doi: 10.1177/1076029610385222
  3. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366 (9467):1607-1621. doi: 10.1016/S0140-6736(05)67660-X
  4. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. The CURE trial investigators. N Engl J Med. 2001;345:494-502. doi: 10.1056/NEJMoa010746
  5. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. doi: 10.1056/NEJMoa050522
  6. Levine GN et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122. doi: 10.1161/CIR.0b013e31823ba622
  7. O,Connor RE, Bossaert L, Arntz HR et al. Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2010;122(suppl 2):S422-S465. doi: 10.1161/CIRCULATIONAHA.110.985549
  8. Всероссийское научное общество кардиологов. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Российские рекомендации. М.; 2007.
  9. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057. doi: 10.1056/NEJMoa0904327
  10. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery, results from the PLATO. J Am Coll Cardiol. 2011;57(6):672-684. doi: 10.1016/j.jacc.2010.10.029
  11. Polinder S, Toett H, Panemann M, Beek E. Methodological approaches for CEA and CUA of injury prevention measures. World Health Organization; 2011.
  12. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» 91500.14.0001-2002.
  13. Государственный реестр предельных отпускных цен. Ссылка активна на 22.06.2016. Доступно по: http://grls.rosminzdrav.ru/PriceLims.aspx
  14. Постановление правительства Москвы №163-IIII от 24.02.2010 г. «Об установлении торговых надбавок к ценам на лекарственные средства». Ссылка активна на 22.06.2016. Доступно по: http://www.garant.ru/hotlaw/moscow/232771/
  15. Сайт Единой информационной системы в сфере закупок. Ссылка активна на 22.06.2016. Доступно по: http://zakupki.gov.ru
  16. Пядушкина Е.А., Герасимова К.В., Омельяновский В.В., Авксентьева М.В., Крысанов И.С. Фармакоэкономический анализ применения антитромбоцитарной терапии тикагрелором и клопидогрелом с целью профилактики сосудистых явлений и смерти у пациентов с острым коронарным синдромом. Медицинские технологии. Оценка и выбор. 2012;10(4):35-45.
  17. Постановление Правительства Москвы от 23 декабря 2014 г. №811-ПП «О Территориальной программе государственных гарантий бесплатного оказания гражданам медицинской помощи в городе Москве на 2015 год и на плановый период 2016 и 2017 годов». Ссылка активна на 22.06.2016. Доступно по: http://www.emcmos.ru/upload/zakon01.pdf
  18. Петров В.И., Дронова Е.П., Лопатин Ю.М. Реваскуляризация миокарда в лечении больных ишемической болезнью сердца с точки зрения клинико-экономических аспектов эффективности. Вестник Волгоградского государственногомедицинского университета. 2010;4 (36):18-22.
  19. Атьков О.Ю., Полубенцева Е.И. Планы ведения больных. Терапия. М.: ГЭОТАР-медиа; 2011.
  20. Антошина И.Н. Клинико-психологические и социально-трудовые особенности больных, перенесших аортокоронарное шунтирование, в амбулаторном периоде реабилитации: Автореф. дис. ... канд. мед. наук. М.; 2002. Ссылка активна на 22.06.2016. Доступно по: http://medical-diss.com/medicina/kliniko-psihologicheskie-i-sotsialno-trudovye-osobennosti-bolnyh-perenesshih-aortokoronarnoe-shuntirovanie-v-ambulatornom
  21. Продолжительность трудового стажа после назначения пенсии по возрасту назначения и виду назначенной пенсии в Российской Федерации в 2011 году, Данные сайта Федеральной службы государственной статистики. Ссылка активна на 22.06.2016. Доступно по:http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/generation
  22. Россия 2015: Статистический справочник. М.: Росстат; 2015

Statistics

Views

Abstract: 422

PDF (Russian): 157

Dimensions

Article Metrics

Metrics Loading ...

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2016 Zyryanov S.K., Belousov D.Y., Afanasyeva E.V., Dumchenko E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies